Francisco Partners Iv, L.P. Sells 471,975 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75. Following the completion of the sale, the insider directly owned 1,127,436 shares of the company’s stock, valued at $3,979,849.08. The trade was a 29.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.

GoodRx Stock Performance

Shares of GoodRx stock opened at $3.45 on Friday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 86.27, a price-to-earnings-growth ratio of 1.72 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The business has a 50-day moving average of $3.13 and a 200 day moving average of $2.63. GoodRx Holdings, Inc. has a 12 month low of $1.77 and a 12 month high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. As a group, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Citigroup upped their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays boosted their price target on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.23.

Institutional Trading of GoodRx

Large investors have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of GoodRx during the 2nd quarter worth $30,000. Technology Crossover Management X Ltd. purchased a new position in GoodRx in the second quarter valued at $4,762,000. Bank of New York Mellon Corp acquired a new stake in GoodRx in the second quarter valued at $540,000. Essential Partners LLC raised its stake in GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after buying an additional 11,295 shares in the last quarter. Finally, Amundi purchased a new stake in GoodRx during the 1st quarter worth about $37,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.